Burgdorf – Ypsomed invests into new subsidiaries to allow even more people with diabetes to benefit from the advantages of insulin pump therapy.
Following the successful and controlled launch of the mylife™ YpsoPump® during 2016 in Germany, the Netherlands and the UK, the Management of the Ypsomed Group has decided in favour of geographic expansion. In addition to the existing home markets such as France, Italy, Switzerland, Austria and Scandinavia, the innovative insulin pump is also to be launched in Belgium, Spain and India during 2017. The mylife™ YpsoPump® is already available in Czechia since January 2017, where the subsidiary was established at the end of 2016, mainly for its distribution.
Ypsomed CEO Simon Michel justifies the investment into geographic expansion as follows:
"The introduction phase of the mylife™ YpsoPump® has shown that it meets the needs of many people with diabetes. Simplicity in training and in use gives many people a certain degree of freedom and independence in their daily therapy and considerably simplifies the process in the pump centres and physicians practices. Furthermore, the competitive situation in the market for insulin pumps is extremely dynamic. Due to this development we foresee excellent opportunities of growing successfully in this highly competitive market and to continue establishing ourselves as a diabetes specialist. All good reasons to exploit important and missing markets inside and outside Europe with additional investments."